Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gan and Lee PharmaceuticalsSHSE:603087 -2.27%90 Return-on-Tangible-Asset is 15.84% as of Jun. 2026, which is 4% below its 10-year median of 16.43. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 83.9% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Gan and Lee Pharmaceuticals's annualizedNet Income for the quarter that ended in Jun. 2026 was ¥1,669 Mil. Gan and Lee Pharmaceuticals's average total tangible assets for the quarter that ended in Jun. 2026 was ¥10,537 Mil. Therefore, Gan and Lee Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 15.84%.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:603087'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -4.49 Med: 16.43 Max: 37.77
Current: 10.9
During the past 13 years, Gan and Lee Pharmaceuticals's highest Return-on-Tangible-Asset was 37.77%. The lowest was -4.49%. And the median was 16.43%.
SHSE:603087's Return-on-Tangible-Asset is ranked better than 83.9% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.96
vs SHSE:603087: 10.90
Gan and Lee Pharmaceuticals (SHSE:603087) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Gan and Lee Pharmaceuticals Return-on-Tangible-Asset Related Terms
Gan and Lee Pharmaceuticals Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals Return-on-Tangible-Asset Chart
SHSE:603087 vs ISRG, BDX, RMD: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 15.84% mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a Return-on-Tangible-Asset of 15.84% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is near median its historical median of 16.43. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #137 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 16.1%.
Is Gan and Lee Pharmaceuticals' Return-on-Tangible-Asset too high?
Gan and Lee Pharmaceuticals' current Return-on-Tangible-Asset of 15.84% is near median its 10-year median of 16.43. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.96. Gan and Lee Pharmaceuticals' value of 15.84% is 1550% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #137 out of 851 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #137 out of 851 companies for Return-on-Tangible-Asset. This places Gan and Lee Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.96. Gan and Lee Pharmaceuticals' value of 15.84% is 1550% above this benchmark. While the company's 10-year median is 16.43 vs. the industry median of 0.96, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.96, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Return-on-Tangible-Asset of 15.84% is 1550% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Return-on-Tangible-Asset is 15.84%, which is near median its own 10-year median of 16.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Return-on-Tangible-Asset is 15.84%, which is near median its 10-year median of 16.43 and 1550% above the Medical Devices & Instruments industry median of 0.96. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Return-on-Tangible-Asset is 15.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
Return-on-Tangible-Asset: 15.84% (near median its 10-year median of 16.43)
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
Industry Position: 1550% above the Medical Devices & Instruments median (#137 of 851)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
